Proteomic Characterisation of the Plasma Proteome in Extramedullary Multiple Myeloma Identifies Potential Prognostic Biomarkers

多发性骨髓瘤 蛋白质组 等离子体电池 医学 计算生物学 病理 癌症研究 生物 免疫学 生物信息学
作者
Katie Dunphy,Despina Bazou,Paul Dowling,Peter O’Gorman
出处
期刊:Blood [Elsevier BV]
卷期号:140 (Supplement 1): 10058-10059 被引量:1
标识
DOI:10.1182/blood-2022-159935
摘要

Introduction: Extramedullary multiple myeloma (EMM) is an aggressive manifestation of multiple myeloma (MM) reported to occur in approximately 7% of patients at diagnosis and up to 30% of patients at relapse. EMM is characterised by the spread of malignant plasma cells from the bone marrow microenvironment to distal tissues or organs. It is associated with an adverse prognosis, correlating with a significant reduction in overall survival. Currently there are no validated, established biomarkers to predict EMM. Furthermore, EMM is often treated similarly to high-risk MM with no targeted therapeutic strategies. In-depth proteomic studies on EMM are lacking and the underlying molecular mechanisms that facilitate extramedullary transition are yet to be fully defined. Novel biomarkers and therapeutic targets are urgently required. To enhance our understanding of EMM and to identify novel prognostic biomarkers, we performed a mass spectrometry-based proteomic study on plasma from MM patients with and without extramedullary spread. Methods: Label-free liquid chromatography mass spectrometric analysis of age and gender-matched medullary MM (n=8) and EMM (n=9) blood plasma samples was carried out using a Thermo Q-Exactive mass spectrometer (Thermo Fisher Scientific). Proteome Discoverer 2.2 using Sequest HT (Thermo Fisher Scientific) and a percolator were employed for the identification of peptides and proteins. Several parameters were defined for protein identification: MS/MS mass tolerance was set to 0.02 Da; peptide mass tolerance was set to 10ppm; methionine oxidation was set as a variable modification; carbamido-methylation was set as a fixed modification; and up to two missed cleavages were tolerated. Peptide probability was set to high confidence. Data was imported into Perseus (1.6.14.0) for further analysis. Proteins with less than 70% valid values were removed from the analysis. Proteins of interest were identified based on an FDR-adjusted p-value ≤0.1, fold change >1.5 between experimental groups. Six proteins were selected for further validation using DuoSet enzyme linked immunosorbent assay (ELISA) kits (R&D Systems). We performed receiver operating characteristic (ROC) and area under the curve (AUC) analyses to determine the diagnostic potential of the validated proteins. Results: The median age was 65. Survival analysis revealed a statistically significant change in overall survival (OS) between the two patient cohorts (Log-rank = 3.977, P = 0.046). The median OS of patients with EMM and those without extramedullary spread was 19 months and 83 months, respectively. Our quantitative MS-based proteomic analysis identified 21 proteins of differential abundance between EMM and MM patient plasma (False discovery rate (FDR)-adjusted p-value < 0.1, fold change > 1.5) (Fig. 1A). Antibody-based validation using ELISAs was performed on six proteins (vascular cell adhesion molecule 1 (VCAM1), hepatocyte growth factor activator (HGFA), pigment epithelial-derived factor (PEDF), alpha-2-macroglobulin (A2M), cholinesterase (BCHE), aminopeptidase N (CD13)). VCAM1, HGFA and PEDF were confirmed as being significantly altered between the two cohorts (FDR-adjusted p-value < 0.05). VCAM1, HGFA and PEDF were subject to ROC analyses, demonstrating high discriminatory power for EMM diagnosis (AUC = 0.96, AUC = 0.85, and AUC = 0.97, respectively). The diagnostic efficacy was further enhanced by combining these biomarkers using a logistic regression model (AUC = 1). Conclusion: Our mass spectrometry and antibody-based study identified proteins of differential abundance in the blood plasma of MM patients with and without extramedullary spread. VCAM1, PEDF and HGFA represent promising predictive biomarkers and warrant further investigation in a larger cohort of patients. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
科研人完成签到,获得积分10
刚刚
飞云完成签到 ,获得积分10
1秒前
满天星辰独览完成签到 ,获得积分10
1秒前
九天完成签到 ,获得积分10
2秒前
Bin_Liu发布了新的文献求助10
2秒前
feiyang完成签到 ,获得积分10
3秒前
超帅无色发布了新的文献求助10
3秒前
QCB完成签到 ,获得积分10
5秒前
爱笑半雪完成签到,获得积分10
6秒前
CipherSage应助知犯何逆采纳,获得10
7秒前
淡淡月饼完成签到,获得积分10
11秒前
11秒前
超帅无色完成签到,获得积分20
12秒前
snow完成签到 ,获得积分10
13秒前
16秒前
dream完成签到 ,获得积分10
18秒前
唐唐发布了新的文献求助10
18秒前
史克珍香完成签到 ,获得积分10
24秒前
晓风完成签到,获得积分10
27秒前
CR完成签到 ,获得积分10
28秒前
mammer应助超帅无色采纳,获得10
29秒前
科研通AI2S应助科研通管家采纳,获得10
29秒前
所所应助科研通管家采纳,获得10
30秒前
Owen应助科研通管家采纳,获得10
30秒前
30秒前
lilylwy完成签到 ,获得积分0
30秒前
li完成签到 ,获得积分10
30秒前
可爱的函函应助唐唐采纳,获得10
35秒前
小石头完成签到,获得积分10
37秒前
量子星尘发布了新的文献求助10
41秒前
xiaoxiaoxingchen完成签到 ,获得积分10
41秒前
laohu完成签到,获得积分10
42秒前
风格完成签到,获得积分10
42秒前
大橙子发布了新的文献求助150
44秒前
八点必起完成签到,获得积分10
45秒前
sduweiyu完成签到 ,获得积分10
46秒前
hyf完成签到 ,获得积分10
47秒前
aldehyde应助芊芊要发SCI采纳,获得10
48秒前
Twinkle完成签到,获得积分10
50秒前
Eureka完成签到,获得积分10
52秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038157
求助须知:如何正确求助?哪些是违规求助? 3575869
关于积分的说明 11373842
捐赠科研通 3305650
什么是DOI,文献DOI怎么找? 1819255
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022